Dr. Tycel Phillips discusses the FDA approval of a Calquence combo in MCL, making it the first and only BTK inhibitor ...

AstraZeneca’s CALQUENCE® (acalabrutinib) in combination with bendamustine and rituximab has been approved in the US for the treatment of adult patients with previously untreated mantle cell ...

Dr. Tycel Phillips discusses the implications of the FDA approval of Calquence plus bendamustine and Rituxan in untreated MCL ...

AstraZeneca has received another boost to its aspirations in oncology with the FDA approval of Calquence, a next generation treatment for mantle cell lymphoma (MCL). Calquence (acalabrutinib ...

Findings showed acalabrutinib with bendamustine and rituximab (BR) reduced the risk of disease progression or death by 27% compared with placebo plus BR. The Food and Drug Administration (FDA) has ...

In this video, Jennifer A. Woyach, MD, discusses results from the AMPLIFY trial, presented at ASH Annual Meeting and Exhibition.The trial evaluated fixed-duration acalabrutinib (Calquence, AstraZeneca ...

Chemotherapy is the standard treatment, but relapse is common. Acalabrutinib, marketed under the brand name Calquence, is a small molecule designed to block Bruton’s tyrosine kinase (BTK), an ...

The latest approval allows Calquence use with bendamustine and rituximab for adults with newly diagnosed mantle cell lymphoma who are not eligible to undergo hematopoietic stem cell ...

FDA fully approves AstraZeneca's Calquence combo therapy, reducing MCL progression/death risk by 27% in Phase 3 ECHO trial. Median progression-free survival extended to 66.4 months with Calquence vs.

AstraZeneca's Calquence has hit the mark in the phase 3 AMPLIFY trial in chronic lymphocytic leukaemia (CLL), a study that chief executive Pascal Soriot recently said could be a "blockbuster ...